A practical reference on freeze-thaw cycle: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-18 and is reviewed periodically as new material appears.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Lisdexamphetamine was developed by Robert Oberlender at New River Pharmaceuticals, under the name NRP104, before being bought by Takeda Pharmaceuticals through its acquisition of Shire Pharmaceuticals, prior to market release. It was developed to create a longer-lasting and less-easily abused version of dextroamphetamine, as the requirement of conversion into dextroamphetamine via enzymes in the red blood cells delays its onset of action, regardless of the route of administration. In February 2007, the US Food and Drug Administration (FDA) approved lisdexamphetamine for the treatment of ADHD. In August 2009, Health Canada approved the marketing of lisdexamphetamine for prescription use. In January 2015, lisdexamphetamine was approved by the FDA for the treatment of binge eating disorder in adults. The FDA gave tentative approval to generic formulations of lisdexamphetamine in 2015. The expiration date for patent protection of lisdexamphetamine in the US was 24 February 2023. The Canadian patent expired 20 years from the filing date of 1 June 2004. Production quotas for 2016 in the United States were 29,750 kg.
== Other foreign interventions == Other European Parliament corruption scandals involve foreign interventions. Green Party MEP Viola von Cramon-Taubadel said that Kazakhstan, Azerbaijan and Russia also "systematically purchased influence over an extended period". In 2025 foreign interventions by China were investigated.
=== Relations === The pelvic cavity of the true pelvis has the pelvic floor as its inferior boundary (and the pelvic brim as its superior boundary). The perineum has the pelvic floor as its superior boundary. Posteriorly, the pelvic floor extends into the anal triangle.
== Invertebrates == In insects, synephrine has been found to be a very potent agonist at many invertebrate octopamine receptor preparations, and is even more potent than octopamine at a locust (Schistocerca americana gregaria) nerve-muscle preparation. Synephrine (racemic) is also more potent than octopamine (racemic) at inducing light-emission in the firefly (Photinus species) light organ. Synephrine exhibits similarly high potency in stimulating adenylate cyclase activity and in decreasing clotting time in lobster (Homarus americanus) hematocytes. Racemic synephrine was found to increase cAMP in the abdominal epidermis of the blood-sucking bug, Rhodnius prolixus. Rachinsky reported that synephrine was equipotent with octopamine in stimulating JH (juvenile hormone) release in the corpora allata of honey bee (Apis mellifera), but Woodring and Hoffmann found that synephrine had no effect on the synthesis of JH III, in in vitro preparations from the cricket, Gryllus bimaculatus.
=== Grand Lodge of South Carolina === On March 27, 1818, the Grand Lodge of South Carolina chartered La Constancia Lodge, No. 50. On March 31, 1820, they chartered La Amenidad Lodge, No. 52. Both of these were chartered in Havana. In 1821, the Grand Lodge of Ancient Freemasons sent a communication to the Grand Lodge of South Carolina that a new Grand Lodge had been formed in Cuba, and La Amenidad Lodge, No. 52 had expressed its desire to transfer to the new Grand Lodge. The Grand Lodge of South Carolina accepted the arrangement. However, La Constancia Lodge, No. 50, remained a part of the Grand Lodge of South Carolina until its members surrendered its warrant around the year 1824, stating that their decision was made "in consequence of the religious and political persecutions to which they were subjected."
Sources: en.wikipedia.org
=== Air purifier distribution === On Friday, July 21, 2023, Illinois Governor JB Pritzker and the Illinois Department of Public Health announced they were partnering with SHIELD Illinois to distribute air purifiers to licensed Illinois Day Care outside of the city of Chicago. The purifiers were purchased with $10 million of federal funds through the CDC's Epidemiology and Laboratory Capacity for Prevention and Control (ELC) Reopening Schools Program. SHIELD Illinois will use the extensive logistics capabilities developed serving over 2,300 locations during the pandemic to distribute the filters across the state.
== Physiologic effects == BNP decreases sodium reabsorption in the distal convoluted tubule (interaction with NCC) and cortical collecting duct of the nephron via guanosine 3',5'-cyclic monophosphate (cGMP) dependent phosphorylation of ENaC.
=== Disease diagnosis and monitoring === Disease diagnosis and monitoring of therapeutic efficacy is possible by detecting several biomarkers in body fluid. However, current tissue fluid extraction methods are pain-inducing, and it may take up to hours or days for samples to be analyzed in medical laboratories. MNs could collect body fluid in an almost painless manner, and it could provide immediate diagnosis when combined with a sensor. MNs allow penetration through the epidermis but not long enough to compress nerves in deeper layers, and thus, they are minimally invasive and almost painless. MNs' precision also allow the extraction of fluid surrounding diseased tissues, which may contain higher concentration of different biomarkers and specific biomarkers that are not present in the systemic circulation. These fluids provide more clinically significant and accurate values than those extracted from the systemic circulation, subsequently lowering the chances of underestimation of disease severity, especially for localized diseases. Furthermore, MNs are capable of providing (near) real-time diagnosis, and it is easily administrated with simple procedures. Thus, MNs are potential candidates for Point-of-care (PoC) testing which could be conducted bedside. Hollow MNs and hydrogel MNs could be used to diagnose and monitor several diseases including Cataracts, Diabetes, Cancer, and Alzheimer's disease. For instance, hollow glass MNs and hydrogel MNs could extract skin interstitial fluid for the detection of glucose levels.
== Properties == The S−S bond dissociation energy is 305±21 kJ/mol, about 80 kJ/mol stronger than the S−S bond in diphenyldisulfide. At temperatures above 150 °C (302 °F), S2F10 decomposes slowly (disproportionation) into SF6 and sulfur tetrafluoride (SF4):
Hosokawa Micron Powder Systems is an American company located in Summit, New Jersey, which designs and manufactures equipment for size reduction, classification and mixing of chemical, pharmaceutical and food materials. The company was started in 1923 by Louis Ruprecht named Pulverizing Company and was later bought by the Hosokawa Micron Group in 1985.
Sources: en.wikipedia.org
Soy sauce (醬油, jiàngyóu) is considered almost as old as soy paste—a type of fermented paste (jiàng, 醬) obtained from soybeans—which had appeared during the Western Han dynasty (206 BC – 220 AD) and was listed in the bamboo slips found in the archaeological site Mawangdui (馬王堆). There are several precursors of soy sauce that are associated products with soy paste. The oldest is qingjiang (清醬), which appeared in AD 40 and was listed in Simin Yueling (四民月令). Others are jiangqing (醬清), chizhi (豉汁) and chiqing (豉清), which were recorded in the Qimin Yaoshu (齊民要術) in AD 540. By the time of the Song dynasty (960–1279 AD), the term jiàng yóu (醬油) had become the accepted name for the liquid condiment, documented in two books: Shanjia Qinggong (山家清供) and Pujiang Wushi Zhongkuilu (浦江吳氏中饋錄) during the Song dynasty (960–1279 AD). Like many salty condiments, soy sauce was originally a way to stretch salt, historically an expensive commodity. During the Zhou dynasty of ancient China, fermented fish with salt was used as a condiment in which soybeans were included during the fermentation process. By the time of the Han dynasty, this had been replaced with the recipe for soy paste and its by-product soy sauce, by using soybeans as the principal ingredient, with fermented fish-based sauces developing separately into fish sauce.
Sofer, G.; Hagel, L. (1997). Handbook of Process Chromatography: A guide to Optimization, Scale-up, and Validation. Academic Press, 158-161. ISBN 0-12-654266-X Tours, N. and Sandle, T. Comparison of dry-heat depyrogenation using three different types of Gram-negative bacterial endotoxin, European Journal of Parenteral and Pharmaceutical Sciences, Volume 13, No.1, 2008, pp. 17–20
How turtles breathe has been the subject of much study. To date, only a few species have been studied thoroughly enough to get an idea of how those turtles breathe. The varied results indicate that turtles have found a variety of solutions to this problem. The difficulty is that most turtle shells are rigid and do not allow for the type of expansion and contraction that other amniotes use to ventilate their lungs. Some turtles, such as the Indian flapshell (Lissemys punctata), have a sheet of muscle that envelops the lungs. When it contracts, the turtle can exhale. When at rest, the turtle can retract the limbs into the body cavity and force air out of the lungs. When the turtle protracts its limbs, the pressure inside the lungs is reduced, and the turtle can suck air in. Turtle lungs are attached to the inside of the top of the shell (carapace), with the bottom of the lungs attached (via connective tissue) to the rest of the viscera. By using a series of special muscles (roughly equivalent to a diaphragm), turtles are capable of pushing their viscera up and down, resulting in effective respiration, since many of these muscles have attachment points in conjunction with their forelimbs (indeed, many of the muscles expand into the limb pockets during contraction). Breathing during locomotion has been studied in three species, and they show different patterns. Adult female green sea turtles do not breathe as they crutch along their nesting beaches. They hold their breath during terrestrial locomotion and breathe in bouts as they rest.
=== Structure === The human IRAP gene encodes a type II transmembrane protein that consists of three distinct domains: an N-terminal cytoplasmic domain containing 109 amino acids, a transmembrane domain of 23 amino acids, and an intraluminal (or extracellular) domain composed of 893 amino acids. The C-terminal intra-endosomal domain harbours the Zn-binding motif known as HEXXH(X)18E, as well as the exopeptidase motif GAMEN. These two motifs are also present in ERAP1 and ERAP2 and are shared among all members of the M1 family of aminopeptidases. The C-terminal domain has been crystallized as a dimer, each monomer consisting of four continuous domains and forming a closed hollow structure with the active site at its center. Domain I (residues 171–365) forms an extensive β-sandwich with a seven-stranded β-saddle flanked on either side by three- and four-stranded β-sheets. Domain II (residues 366–615) contains the catalytic site with a Zn ion at its center. The catalytic Zn ion is coordinated by His464, His468, and Glu487 of HEXXH(X)18-E zinc-binding motif. Domain III (residues 616–704) adopts a β-sandwich fold consisting of three and four-stranded β-sheets and forms a bridge between domains II and IV. Domain IV (residues 705–1025) consists of α-helices and assemble in a "bowl-like" shape. The active site of IRAP is capped by domain IV to form a large, mostly enclosed cavity adjacent to the Zn ion.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.